The responsiveness to treatment in RA in studies with tocilizumab—another IL-6R inhibitor—was proven to be predicted by certain single nucleotide polymorphisms (SNPs) in the IL6R gene [32,33,34]. Here, IL6R is linked to rheumatoid arthritis.